| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |